Ella Ioffe

4.9k total citations · 2 hit papers
24 papers, 3.6k citations indexed

About

Ella Ioffe is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Ella Ioffe has authored 24 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 13 papers in Oncology and 7 papers in Immunology. Recurrent topics in Ella Ioffe's work include Angiogenesis and VEGF in Cancer (8 papers), Cancer Immunotherapy and Biomarkers (6 papers) and CAR-T cell therapy research (5 papers). Ella Ioffe is often cited by papers focused on Angiogenesis and VEGF in Cancer (8 papers), Cancer Immunotherapy and Biomarkers (6 papers) and CAR-T cell therapy research (5 papers). Ella Ioffe collaborates with scholars based in United States, Canada and Germany. Ella Ioffe's co-authors include George D. Yancopoulos, John S. Rudge, Susan D. Croll, Jocelyn Holash, Elena Burova, Gavin Thurston, Donald M. McDonald, Leorah Ross, Nicole L. Glazer and James P. Fandl and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Medicine.

In The Last Decade

Ella Ioffe

23 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

VEGF-Trap: A VEGF blocker with potent antitumor effects

2002 1.3k citations Jocelyn Holash, Nikolaos G. Papadopoulos et al. Proceedings of the National Academy of Sciences profile →
Angiopoietin-1 protects the adult vasculature against plasma leakage

2000 1.1k citations Gavin Thurston, John S. Rudge et al. Nature Medicine profile →

Peers

Countries citing papers authored by Ella Ioffe

Since Specialization

Citations

This map shows the geographic impact of Ella Ioffe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ella Ioffe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ella Ioffe more than expected).

Fields of papers citing papers by Ella Ioffe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ella Ioffe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ella Ioffe. The network helps show where Ella Ioffe may publish in the future.

Co-authorship network of co-authors of Ella Ioffe

This figure shows the co-authorship network connecting the top 25 collaborators of Ella Ioffe. A scholar is included among the top collaborators of Ella Ioffe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ella Ioffe. Ella Ioffe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Single cell–resolved cellular, transcriptional, and epigenetic changes in mouse T cell populations linked to age-associated immune decline 2025 ·Proceedings of the National Academy of Sciences ·(unknown), Elena Burova, (unknown), Min Ni, Christina Adler, Yi Wei, Nicole Negron, (unknown), Yu Bai, Tea Shavlakadze, Ella Ioffe, (unknown), Adolfo A. Ferrando, David J. Glass	2
2	Human CD4 cytotoxic T lymphocytes mediate potent tumor control in humanized immune system mice 2023 ·Communications Biology ·(unknown), (unknown), (unknown), (unknown), Namita Gupta, (unknown), Davor Frleta, (unknown), Tomasz B. Owczarek, (unknown), Lynn E. Macdonald, Andrew Murphy, Gavin Thurston, Markus Mohrs, Ella Ioffe, Yi-Fen Lu	8
3	1171 CLN-418, a clinical-stage B7H4 x 4–1BB bispecific antibody with potential to treat patients with a wide range of solid tumors 2023 ·SHILAP Revista de lepidopterología ·Ella Ioffe, Naveen K. Mehta, Kristan Meetze, Irina M. Shapiro, (unknown), (unknown), Yun He, Patrick A. Baeuerle, Jennifer S. Michaelson	0
4	Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3 –Knockin Mice 2019 ·Molecular Cancer Therapeutics ·Elena Burova, Aynur Hermann, Jie Dai, Erica Ullman, Gábor Halász, Terra Potocky, (unknown), Matt Liu, (unknown), Amy Woodruff, (unknown), Ashique Rafique, William Poueymirou, Joel Martin, Douglas MacDonald, William C. Olson, Andrew Murphy, Ella Ioffe, Gavin Thurston, Markus Mohrs	62
5	Abstract A174: The anti-LAG-3 antibody REGN3767 promotes immune activation in the tumor microenvironment and enhances antitumor activity of anti-PD-1 antibody REGN2810 in PD-1/LAG-3 humanized mice 2019 ·Cancer Immunology Research ·Elena Burova, (unknown), (unknown), Wen Zhang, William C. Olson, Markus Mohrs, Gavin Thurston, Ella Ioffe	1
6	Resistance to Anti-VEGF Therapy Mediated by Autocrine IL6/STAT3 Signaling and Overcome by IL6 Blockade 2016 ·Cancer Research ·Alexandra Eichten, (unknown), Alexander P. Adler, Li Zhang, Ella Ioffe, Asma Parveen, George D. Yancopoulos, John S. Rudge, Israel Lowy, Hsin Chieh Lin, Douglas MacDonald, Christopher Daly, Xunbao Duan, Gavin Thurston	47
7	Abstract 266: Antitumor activity of REGN2810, a fully human anti-PD-1 monoclonal antibody, against MC38.Ova tumors grown in immune-competent humanized PD-1 mice 2015 ·Cancer Research ·Elena Burova, (unknown), William Poueymirou, Venus Lai, (unknown), Dimitris Skokos, Nicholas Papadopoulos, (unknown), Israel Lowy, Ella Ioffe, Gavin Thurston	1
8	Abstract 5035: Blockade of VEGF with ziv-aflibercept (VEGF Trap) enhances anti-tumor efficacy of CTLA-4 blocking antibody in an Fc dependent manner 2014 ·Cancer Research ·Elena Burova, Ella Ioffe, (unknown), (unknown), Gaurav Tyagi, (unknown), John F. Rudge, Israel Lowy, Gavin Thurston	2
9	Angiopoietin-1 therapy enhances fibrosis and inflammation following folic acid-induced acute renal injury 2008 ·Kidney International ·David A. Long, Karen Price, Ella Ioffe, (unknown), Luigi Gnudi, Kathryn White, George D. Yancopoulos, John S. Rudge, Adrian S. Woolf	52
10	Pharmacologic Blockade of Angiopoietin-2 Is Efficacious against Model Hemangiomas in Mice 2006 ·Journal of Investigative Dermatology ·Betsy N. Perry, Baskaran Govindarajan, Sulochana S. Bhandarkar, Ulla G. Knaus, (unknown), (unknown), (unknown), Allie M. Sohn, Francesca Cerimele, Dan Dumont, Albert Losken, Joseph K. Williams, Lawrence F. Brown, Xiaolian Tan, Ella Ioffe, George D. Yancopoulos, Jack L. Arbiser	84
11	Angiopoietin-2 functions as an autocrine protective factor in stressed endothelial cells 2006 ·Proceedings of the National Academy of Sciences ·Christopher Daly, Elizabeth Pasnikowski, Elena Burova, Vivian W.Y. Wong, Thomas H. Aldrich, Jennifer Griffiths, Ella Ioffe, Thomas J. Daly, James P. Fandl, Nikolaos G. Papadopoulos, Donald M. McDonald, Gavin Thurston, George D. Yancopoulos, John S. Rudge	203
12	The anti-inflammatory actions of angiopoietin-1 2005 ·Birkhäuser Basel eBooks ·Gavin Thurston, John S. Rudge, Ella Ioffe, Nicholas Papadopoulos, Christopher Daly, (unknown), Thomas J. Daly, Stanley J. Wiegand, George D. Yancopoulos	16
13	Angiopoietin-1 modulates endothelial cell function and gene expression via the transcription factor FKHR (FOXO1) 2004 ·Genes & Development ·Christopher Daly, Vivian W.Y. Wong, Elena Burova, Yi Wei, Stephanie M. Zabski, Jennifer Griffiths, Ka‐Man Venus Lai, Hsin Chieh Lin, Ella Ioffe, George D. Yancopoulos, John S. Rudge	261
14	Inhibition of IL-1 Blocks Corneal Inflammation and Neovascularization 2003 ·Investigative Ophthalmology & Visual Science ·J. Cao, R.A. Renard, Hang Song, Ella Ioffe, (unknown), J.S. Rudge, Ellen Koehler-Stec, George D. Yancopoulos, Stanley J. Wiegand	1
15	Suppression of Diabetic Retinopathy with Angiopoietin-1 2002 ·American Journal Of Pathology ·Antonia M. Joussen, Vassiliki Poulaki, Akitaka Tsujikawa, Wenying Qin, Tamim Qaum, (unknown), Y Moromizato, Sven–Erik Bursell, (unknown), John S. Rudge, Ella Ioffe, George D. Yancopoulos, Anthony P. Adamis	164
16	VEGF-Trap: A VEGF blocker with potent antitumor effects breakdown → 2002 ·Proceedings of the National Academy of Sciences ·Jocelyn Holash, (unknown), Nikolaos G. Papadopoulos, Susan D. Croll, (unknown), Michelle Russell, Patricia Boland, (unknown), Donna Hylton, Elena Burova, Ella Ioffe, Tammy Huang, Czeslaw Radziejewski, Kevin M. Bailey, James P. Fandl, (unknown), Stanley J. Wiegand, George D. Yancopoulos, John S. Rudge	1325
17	Angiopoietin-1 protects the adult vasculature against plasma leakage breakdown → 2000 ·Nature Medicine ·Gavin Thurston, John S. Rudge, Ella Ioffe, (unknown), Leorah Ross, Susan D. Croll, Nicole L. Glazer, Jocelyn Holash, Donald M. McDonald, George D. Yancopoulos	1055
18	Absence of Soluble Leptin Receptor in Plasma fromdbPas/dbPas and Otherdb/db Mice 1998 ·Journal of Biological Chemistry ·Li Cai, Ella Ioffe, (unknown), Eileen P. Connolly, Jeffrey M. Friedman	55
19	Abnormal regulation of the leptin gene in the pathogenesis of obesity 1998 ·Proceedings of the National Academy of Sciences ·Ella Ioffe, Byoung C. Moon, Eileen P. Connolly, Jeffrey M. Friedman	89
20	Complex N-glycans in Mgat1 null preimplantation embryos arise from maternal Mgat1 RNA 1997 ·Glycobiology ·Ella Ioffe, Yun Liu, Pamela Stanley	30

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact